The Top 10 Generic Pharmaceutical Companies

Positioning, Performance and SWOT Analyses

Publication Date	July 2008
Publisher	Business Insights
Product Type	Report
Pages	178
ISBN Number	not applicable
Product Code	RBI00248

Price

£1,995.00
approximately: $2,906 | €2,302

PDF

PRINT £2,045 ($2,979 | €2,360)

Order above formats by FAX

Summary

The Top 10 Generic Pharmaceutical Companies Positioning, performance and SWOT analyses

The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004-2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry. Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs. However, the generics market is changing due to the threat from authorized generics, competition from players in emerging countries and increasing consolidation. Teva's acquisition of Barr Pharmaceuticals is the latest example of companies attempting to improve their market strength and geographical reach via divestments and acquisitions.

'The Top 10 Generic Pharmaceutical Companies' is a new report published by Business Insights that analyzes the size, structure and competitive landscape of the global generics market. The top 10 generics companies are assessed based on their market shares, product performances, therapeutic focus and future outlook, and the key issues and challenges facing these companies are examined. The latest industrial trends and developments are assessed across the generics markets of the UK, France, Germany, Italy, Spain and the US. This report also evaluates the strengths and weaknesses of the leading players and provides insights into the opportunities and threats that face them.

Assess the structure, competitive landscape and latest developments in the global generics market, compare the performances and portfolios of leading companies and benchmark their strategies with this new report
Compare the performances and growth strategies of leading generics companies and discover the business models that hold the key to future growth with this new report.

Some key findings from this report

The global generics market reached $90.7m in 2007, representing a three-year CAGR of 12.1%. Sales of generic drugs are expected to increase by 14-15% in 2008, as compared with branded pharmaceutical growth of 6-7%. Much of this growth will be driven by the introduction of pro-generic reforms to major markets
The top 10 generics companies accounted for 28.5% of the global market in 2007. Many leading players are actively updating their product portfolios, seeking growth opportunities in emerging markets, pursuing cost optimization and investing in R&D capabilities
The US attained generics sales worth $25.4m in 2007, accounting for 26.3% of global market. However, the generics markets of EU countries have a higher growth rate than the US, and accounted for 14.2% of the global sales in 2007
Generics companies are currently facing a number of major challenges including continued pricing pressure, authorized generics, a lack of patient awareness and distrust among healthcare prescribers
The nervous system (NS) and cardiovascular system (CVS) were the largest generics therapy areas among the top 10 companies in this report, with a 2007 market share of 31% and 28% respectively

Top reasons to order your copy today

Benchmark the top 10 generic companies over the 2004-07 period, and use detailed company analysis to measure the performances and outlooks of major players including Novartis, Teva, Mylan, Apotex, Ratiopharm, Pfizer, Sanofi-Aventis, Watson, Bayer and Stada
Assess the market dynamics, sales volumes, growth drivers within major generics markets with this report's analysis of countries including France, Germany, Italy, Spain, the UK and the US
Evaluate the strategies of leading generics companies by using this report to measure the success of their currently marketed products and identifying their geographic expansion, product innovation tactics, major acquisitions and divestments and new product launches
Identify the therapeutic focus of the top 10 generics companies, understand how company product portfolios are evolving and examine future growth opportunities within key therapeutic areas
Measure the industrial impact of the latest trends and issues including the implications of patent expirations and the future potential of emerging generics markets such as Brazil, Russia, India and China

Key issues examined in this report

Growing presence of branded companies. Branded Pharma companies are increasingly involved in generics production to win back revenues that would otherwise be lost due to patent expiry. After launching their own authorized generics, branded companies are able to delay and inhibit the entry of pure generic players by undercutting price and market share during the exclusivity period
Rising pressure on pricing. The long term sustainability of generic pharmaceutical companies is coming under threat after government initiatives to promote low cost generics have contributed to product devaluation and reduced profit margins
Increased consolidation. Generic manufacturers are consolidating in order to compete with rising numbers of specialty pharma companies who possess greater scale and R&D capabilities. The regulatory framework for authorized generics also provides easy market access for specialty developers, forcing pure generic players to consolidate in order to achieve greater vertical integration, scale and R&D skills

Your questions answered

What are the latest trends and developments in the major generics markets of the UK, France, Germany, Spain, Italy and the US?
Who are the top 10 global generic pharmaceutical companies and what are their market shares?
Which therapy areas have become the focus of the global top 10 generic companies?
What are the strengths, weaknesses, opportunities and threats facing each of the leading players?
What are the drivers and resistors of growth across major generics markets?
What are the key strategies of the leading generics companies and how do these strategies drive revenue and market share?
What is the future outlook for the global generics industry?

Content

The Top 10 Generic Pharmaceutical Companies
Executive Summary
- Industry overview
- Novartis (Sandoz)
- Teva
- Mylan
- Ratiopharm
- Apotex
- Pfizer (Greenstone)
- Sanofi-Aventis (Winthrop)
- Watson
- Bayer
- Stada
Chapter 1 Introduction
- What is this report about?
- Methodology
Chapter 2 Industry overview
- Summary
- Introduction
- Market overview
- Global generics market: size and growth
- Market overview for the US/5EU
- The US
- The UK
- France
- Germany
- Spain
- Italy
- Top trends in the industry
- Changing paradigms towards emerging markets
- The generics manufacturing base is shifting to low cost hubs
- Growing legislative support for 'follow-on biologics'
- Increasing participation of branded Pharma companies in generics industry
- Consolidation
- Top ten generic companies
- Global ranking
- US/5EU consolidated
- Therapeutic focus of the top 10
- Key marketed products of the top 10
- Geographic focus of the top 10
- US ranking
- EU ranking
Chapter 3 Novartis (Sandoz)
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Focus on difficult-to-make and biosimilar generics
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Size and leading generics position
- Dynamic launches
- Weaknesses
- Development setbacks
- Opportunities
- Strong pipeline
- Threats
- Legal proceedings
Chapter 4 Teva
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Leading generics market position
- Global infrastructure
- Weaknesses
- Distribution model
- Opportunities
- Focus on hospitals and institutional channels
- Threats
- Failure to obtain market exclusivity in the US
Chapter 5 Mylan
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Leading market position in Asia Pacific
- Growth through strategic acquisitions
- Weaknesses
- Dependence on a few key products
- Opportunities
- Growing generics demand
- Threats
- Merck Generics litigations
Chapter 6 Ratiopharm
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Focus on biosimilars
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Leading position in Germany
- Weaknesses
- Dependence on European market
- Opportunities
- Biosimilar filgrastim
- Launch of generic Plavix
- Threats
- Competition in German generics market
Chapter 7 Apotex
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Strategic alliances
- Investments in R&D
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Strong R&D capabilities
- Weaknesses
- Lawsuits relating to patent infringement
- Opportunities
- Expanding global footprint beyond Canada and the US
- Successful tender bid for critical healthcare needs in Africa
- Threats
- Extending market exclusivity period in Canada
- Growing pseudo (authorized) generics market in Canada
Chapter 8 Pfizer (Greenstone)
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Extending generics market share
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Strong market position
- Weaknesses
- Geographic concentration in the US
- Opportunities
- Growth opportunities in emerging markets
- Threats
- Competition in the US generics market
Chapter 9 Sanofi-Aventis (Winthrop)
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Regionalization strategy
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Strong presence in emerging economies
- Weaknesses
- Lack of presence in the US
- Opportunities
- Biosimilar generics in the field of low molecular weight heparin
- Threats
- Low penetration of generics in France
Chapter 10 Watson
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Growing offshore presence
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Global centers of excellence
- Weaknesses
- Dependence on third-party manufacturers
- Opportunities
- Expansion in India
- Threats
- Loss of revenues from Ferrlecit
Chapter 11 Bayer
- Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Building on government initiatives to promote generics
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Strong R&D capabilities
- Weaknesses
- Lack of presence in the US and the UK
- Opportunities
- Focus on emerging economies
- Threats
- Regulatory pressure on generic pricing in Germany
Chapter 12 Stada
Summary
- Business description
- Geographic focus
- Marketed products
- Major therapeutic focus
- Growth strategies
- Cost optimization
- Continuous portfolio expansion
- Acquisitions and divestments
- SWOT analysis
- Strengths
- Low-price cost structure of ALIUD Pharma
- Strong local sales infrastructure
- Weaknesses
- Dependence on third-party suppliers and manufacturers
- Opportunities
- Launch of biosimilar Erythropoietin-zeta
- Expanding footprint in Eastern Europe
- Threats
- Regulatory pressure on generics pricing in Germany
Chapter 13 Conclusion
Introduction
- Generics outperforming the ethical pharmaceutical industry
- Reassessing growth strategies
- Generics competition within the biotech sector
- Stripping-off the pricing advantage
- Outlook
Chapter 14 Appendix
- Glossary
- Index
List of Figures
- Figure 3.1: Global generics market size, 20042007 ($m)
- Figure 3.2: Market position of the global top 10 generics companies, 2007
- Figure 3.3: Generics drivers and resistors - the US
- Figure 3.4: Generics drivers and resistors - the UK
- Figure 3.5: Generics drivers and resistors - France
- Figure 3.6: Generics drivers and resistors - Germany
- Figure 3.7: Generics drivers and resistors - Spain
- Figure 3.8: Generics drivers and resistors - Italy
- Figure 3.9: Emerging markets generic sales, 20032007 ($m)
- Figure 3.10: Pharmaceutical companies and their generic divisions
- Figure 3.11: Top 10 generic companies global market share, 2007
- Figure 3.12: Geographic focus of the top 10 in US/5EU, 2007
- Figure 4.13: Novartis (Sandoz) geographic focus, 20062007
- Figure 4.14: Novartis (Sandoz) therapeutic focus, 2007
- Figure 4.15: Novartis (Sandoz) SWOT analysis
- Figure 5.16: Tevas geographic focus, 20062007
- Figure 5.17: Tevas therapeutic focus, 2007
- Figure 5.18: Teva SWOT analysis
- Figure 6.19: Mylans geographic focus, 20062007
- Figure 6.20: Mylans therapeutic focus, 2007
- Figure 6.21: Mylan SWOT analysis
- Figure 7.22: Ratiopharms geographic focus, 20062007
- Figure 7.23: Ratiopharms therapeutic focus, 2007
- Figure 7.24: Ratiopharm SWOT analysis
- Figure 8.25: Apotexs geographic focus, 20062007
- Figure 8.26: Apotexs therapeutic focus, 2007
- Figure 8.27: Apotex SWOT analysis
- Figure 9.28: Pfizers (Greenstone) geographic focus, 20062007
- Figure 9.29: Pfizers (Greenstone) therapeutic focus, 2007
- Figure 9.30: Pfizer (Greenstone) SWOT analysis
- Figure 10.31: Sanofi-Aventis (Winthrop) geographic focus, 20062007
- Figure 10.32: Sanofi-Aventis (Winthrop) therapeutic focus, 2007
- Figure 10.33: Sanofi-Aventis (Winthrop) SWOT analysis
- Figure 11.34: Watsons therapeutic focus, 2007
- Figure 11.35: Watson SWOT analysis
- Figure 12.36: Bayers geographic focus, 20062007
- Figure 12.37: Bayers therapeutic focus, 2007
- Figure 12.38: Bayer SWOT analysis
- Figure 13.39: Stadas geographic focus, 20062007
- Figure 13.40: Stadas therapeutic focus, 2007
- Figure 13.41: Stada SWOT analysis
- Figure 14.42: Comparative analysis of top 10 generic companies
List of Tables
- Table 3.1: Total generic sales in the US/5EU, 20032007 ($m)
- Table 3.2: Generic sales by volume in the US/5EU, 20032007 (Standard units m)
- Table 3.3: Biologics going off patent in the US, 20082011
- Table 3.4: Top 10 generic companies sales in the US/5EU, 20032007 ($m)
- Table 3.5: Largest therapy areas for generics for the top 10, 2007 ($m)
- Table 3.6: Market share by therapy area in the US/5EU generics market, 20062007
- Table 3.7: Top 10 generics by sales value in the US/5EU, 2007 ($m)
- Table 3.8: Top 10 generic companies in the US, 20032007 ($m)
- Table 3.9: Top 10 generics companies in 5EU, 20032007 ($m)
- Table 4.10: Novartis (Sandoz) snapshot
- Table 4.11: Novartis (Sandoz) top 10 marketed products sales, 20062007 ($m)
- Table 5.12: Teva snapshot
- Table 5.13: Teva's top 10 marketed products sales, 20062007 ($m)
- Table 6.14: Mylan snapshot
- Table 6.15: Mylan's top 10 marketed products sales, 20062007 ($m)
- Table 7.16: Ratiopharm snapshot
- Table 7.17: Ratiopharm's top 10 marketed products sales, 20062007 ($m)
- Table 8.18: Apotex snapshot
- Table 8.19: Apotex' top 10 marketed products sales, 20062007 ($m)
- Table 9.20: Pfizer (Greenstone) snapshot
- Table 9.21: Pfizers (Greenstone) top 10 marketed products sales, 20062007 ($m)
- Table 10.22: Sanofi-Aventis (Winthrop) snapshot
- Table 10.23: Sanofi-Aventis (Winthrop) top 10 marketed products sales, 20062007 ($m)
- Table 11.24: Watson snapshot
- Table 11.25: Watson's top 10 marketed products sales, 20062007 ($m)
- Table 12.26: Bayer snapshot
- Table 12.27: Bayer's top 10 marketed products sales, 20062007 ($m)
- Table 13.28: Stada snapshot
- Table 13.29: Stadas top 10 marketed products sales, 20062007 ($m)